<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD"><gtr:id>CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD</gtr:id><gtr:name>Locate Therapeutics Limited</gtr:name><gtr:address><gtr:line1>MediCity</gtr:line1><gtr:line2>Thane Road</gtr:line2><gtr:line3>Beeston</gtr:line3><gtr:postCode>NG90 6BH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD</gtr:id><gtr:name>Locate Therapeutics Limited</gtr:name><gtr:address><gtr:line1>MediCity</gtr:line1><gtr:line2>Thane Road</gtr:line2><gtr:line3>Beeston</gtr:line3><gtr:postCode>NG90 6BH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>81833.0</gtr:offerGrant><gtr:projectCost>126815.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>22953.0</gtr:offerGrant><gtr:projectCost>22953.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=132217"><gtr:id>CAC5FB5F-BC7A-449E-A91D-32B681F34E67</gtr:id><gtr:title>Preclinical Proof of Concept for a Cell Therapy Delivery Matrix</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>132217</gtr:grantReference><gtr:abstractText>Emerging cell therapies have vast potential in the treatment of currently incurable diseases; the potential

market for cell-based therapies being over 100 million patients in the US alone. Some of the main targets

include heart disease, diabetes, neurodegenerative diseases, musculoskeletal disorders, spinal cord injury,

stroke, autoimmune diseases and trauma.

A current barrier to success is inefficienct clinical administration of these therapies to the patient. This is due to

underdeveloped methods for presenting the cells that results in the majority of them dying or migrating away

soon after injection.

This project aims to redresss this issue by creating purpose-built delivery vehicles that provide protective

environments and solidify upon injection; thus improving the survival, localisation, and clinical effectiveness of

cell therapy. In this programme of work, we will demonstrate these concepts within clinically-relevant

preclinical models.

Finance Summary Table ? How to complete this sectionmmary</gtr:abstractText><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>104786</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">132217</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>